Home › Companies › AbCellera Biologics Inc. › 2024-2025
Compiled from SEC Form N-PX filings and AbCellera Biologics Inc.’s Form 8-K, filed 2025-06-13 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024 2024-2025
Explore AbCellera Biologics Inc. in the interactive database Compare manager voting policies
These tallies are AbCellera Biologics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-13 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Carl L. G. Hansen, Ph.D. | 141,233,414 | 444,265 | 6,760,498 | -- | -- | Majority: yes |
| Elect Director: Michael Hayden, MBCHB (M.D.), Ph.D. | 121,224,143 | 417,794 | 26,796,240 | -- | -- | Majority: yes |
| The broker non-votes for this Proposal 1 totaled 33,560,807 common shares. Proposal 2 The Company's shareholders approved Proposal 2. | 183,078,982 | 678,941 | 241,151 | -- | -- | Majority: yes |
| Proposal 3 The Company's shareholders approved Proposal 3. | 131,605,595 | 16,469,354 | 363,228 | -- | -- | Majority: yes |
Source: AbCellera Biologics Inc., Form 8-K, filed with the SEC on 2025-06-13 — read the filing on EDGAR.
Each item below shows how the 103 asset managers that disclosed a AbCellera Biologics Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of AbCellera Biologics Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 8 wordings of this item as funds reported it.
55% fund support · no official result
The 97 asset managers below cast 55% of the shares they voted on this item FOR (33,832,421 for, 27,470,571 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 0 | 26,722,392 | 0 | 0 | Against |
| Virtus | 6,133,665 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD & CO LTD | 4,746,417 | 0 | 0 | 0 | For |
| Voya | 4,490,520 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 4,180,768 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 4,105,095 | 0 | 0 | 0 | For |
| NICOLA WEALTH MANAGEMENT LTD. | 1,400,350 | 0 | 0 | 0 | For |
| Lazard | 1,136,653 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 1,126,915 | 0 | 0 | 0 | For |
| BlackRock | 1,073,107 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 1,027,686 | 0 | 0 | 0 | For |
| UI BVK Kapitalverwaltungsgesellschaft mbH | 686,573 | 0 | 0 | 0 | For |
| UBS | 0 | 612,878 | 0 | 0 | Against |
| Polar Asset Management Partners Inc. | 459,400 | 0 | 0 | 0 | For |
| Federated Hermes | 300,000 | 123,308 | 0 | 0 | For |
| Vanguard | 408,544 | 0 | 0 | 0 | For |
| Renaissance | 387,548 | 0 | 0 | 0 | For |
| Citadel | 306,280 | 0 | 0 | 0 | For |
| PIER 88 INVESTMENT PARTNERS LLC | 243,790 | 0 | 0 | 0 | For |
| Guardian Partners Inc. | 200,450 | 0 | 0 | 0 | For |
| Mediolanum International Funds Ltd | 178,337 | 0 | 0 | 0 | For |
| American Century | 169,266 | 0 | 0 | 0 | For |
| Allianz | 123,077 | 0 | 0 | 0 | For |
| Listed Funds Trust | 112,543 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 80,000 | 0 | 0 | 0 | For |
Showing the 25 largest of 97 asset managers. See all 97 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
AbCellera Biologics Inc.’s own tally for this item (“Elect Director: Carl L. G. Hansen, Ph.D.”): 141,233,414 for, 444,265 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 298,484,664 outstanding shares: 47.3% for, 0.2% against (47.5% of the company cast a for/against vote).
The 13 asset managers below cast 100% of the shares they voted on this item FOR (14,428,367 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 13,361,096 | 0 | 0 | 0 | For |
| Virtus | 0 | 0 | 6,133,665 | 0 | Abstain |
| Vanguard | 401,306 | 0 | 0 | 0 | For |
| BlackRock | 188,623 | 0 | 0 | 0 | For |
| Federated Hermes | 150,000 | 0 | 0 | 0 | For |
| Listed Funds Trust | 112,543 | 0 | 0 | 0 | For |
| American Century | 84,633 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 39,000 | 0 | 0 | 0 | For |
| State Street | 30,343 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 21,643 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 18,257 | 0 | 0 | 0 | For |
| ProShares | 12,040 | 0 | 0 | 0 | For |
| Fidelity | 8,883 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
AbCellera Biologics Inc.’s own tally for this item (“Elect Director: Michael Hayden, MBCHB (M.D.), Ph.D.”): 121,224,143 for, 417,794 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 298,484,664 outstanding shares: 41% for, 0.2% against (41% of the company cast a for/against vote).
The 13 asset managers below cast 100% of the shares they voted on this item FOR (14,128,165 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 13,361,096 | 0 | 0 | 0 | For |
| Virtus | 0 | 0 | 6,133,665 | 0 | Abstain |
| Vanguard | 401,306 | 0 | 0 | 0 | For |
| BlackRock | 188,623 | 0 | 0 | 0 | For |
| Federated Hermes | 150,000 | 0 | 0 | 0 | For |
| Listed Funds Trust | 0 | 0 | 112,543 | 0 | Abstain |
| American Century | 0 | 0 | 84,633 | 0 | Abstain |
| Blackstone Alternative Investment Funds | 0 | 0 | 39,000 | 0 | Abstain |
| State Street | 0 | 0 | 30,343 | 0 | Abstain |
| ETFis Series Trust I | 0 | 0 | 21,643 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 18,257 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 12,040 | 0 | Abstain |
| Fidelity | 8,883 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
100% fund support · no official result
The 13 asset managers below cast 100% of the shares they voted on this item FOR (20,562,032 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 13,361,096 | 0 | 0 | 0 | For |
| Virtus | 6,133,665 | 0 | 0 | 0 | For |
| Vanguard | 401,306 | 0 | 0 | 0 | For |
| BlackRock | 188,623 | 0 | 0 | 0 | For |
| Federated Hermes | 150,000 | 0 | 0 | 0 | For |
| Listed Funds Trust | 112,543 | 0 | 0 | 0 | For |
| American Century | 84,633 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 39,000 | 0 | 0 | 0 | For |
| State Street | 30,343 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 21,643 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 18,257 | 0 | 0 | 0 | For |
| ProShares | 12,040 | 0 | 0 | 0 | For |
| Fidelity | 8,883 | 0 | 0 | 0 | For |
100% fund support · no official result
The 3 asset managers below cast 100% of the shares they voted on this item FOR (9,803,037 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TD ASSET MANAGEMENT INC | 9,399,486 | 0 | 0 | 0 | For |
| Desjardins Global Asset Management Inc. | 380,111 | 0 | 0 | 0 | For |
| TD Waterhouse Canada Inc. | 23,440 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (33,872 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Green Alpha Advisors, LLC | 33,862 | 0 | 0 | 0 | For |
| Focus Partners Wealth | 10 | 0 | 0 | 0 | For |
Ranked by the number of AbCellera Biologics Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 298,484,664 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 8.95% |
| 2 | Virtus | 2.05% |
| 3 | BAILLIE GIFFORD & CO LTD | 1.59% |
| 4 | Voya | 1.50% |
| 5 | ORBIMED ADVISORS LLC | 1.40% |
| 6 | ArrowMark Colorado Holdings LLC | 1.38% |
| 7 | NICOLA WEALTH MANAGEMENT LTD. | 0.47% |
| 8 | Lazard | 0.38% |
| 9 | Novo Holdings A/S | 0.38% |
| 10 | BlackRock | 0.36% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Carl L.G. Hansen, Ph.D. | 21.23% | DEF14A |
| Thermopylae Holdings Ltd. | 18.81% | DEF14A |
| Baker Bros. Advisors LP | 9.22% | DEF14A |
| Véronique Lecault, Ph.D. | 4.24% | DEF14A |
| Andrew Booth | 2.04% | DEF14A |
| BlackRock | 1.20% | 13F |
| Two Sigma | 1.05% | 13F |
| Renaissance Technologies | 0.97% | 13F |
| Tryn Stimart | 0.90% | DEF14A |
| Citadel Advisors | 0.67% | 13F |
Percentages above are of 298,484,664 shares outstanding, as reported by AbCellera Biologics Inc. on its Form 10-Q dated 2025-05-05 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AbCellera Biologics Inc.’s 10-Q dated 2025-05-05. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At AbCellera Biologics Inc.'s shareholder meeting held 2025-06-12, in the 2024-2025 proxy season, 103 asset managers reported how they voted in their SEC Form N-PX filings, covering 188 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. AbCellera Biologics Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — the reporting funds cast 55% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.
AbCellera Biologics Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page).